Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Ramipril Capsules USP 1.25mg, 2.5mg, 5mg and 10mg. The product has a market size of approximately $95 million for the twelve months ending September 2010 according to IMS.
Ramipril Capsules USP 1.25mg, 2.5mg, 5mg and 10mg is the generic equivalent to the reference listed drug Altace Capsules 1.25mg, 2.5mg, 5mg and 10mg of King Pharmaceuticals. Under the Cardiovascular (CVS) therapeutic segment Ramipril Capsules are indicated for the treatment of hypertension. Aurobindo now has a total of 138 ANDA approvals (108 Final approvals and 30 tentative approvals) from USFDA.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterological, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: